Article ID | Journal | Published Year | Pages | File Type |
---|---|---|---|---|
8454065 | Lung Cancer | 2018 | 5 Pages |
Abstract
Forty-three patients were included. BMs were locally pretreated in 34 (79%) patients and active in 16 (37%) patients. Median follow-up was 5.7 (95% CI: 2.7-8.4) months. IORR and extracerebral response rate were, respectively, 9% (95% CI: 3-23%) and 11% (95% CI: 4-26%). Intracerebral control rate was 51% (95% CI: 37-66%). Median intracerebral and general PFS lasted 3.9 (95% CI: 2.8-11.1) and 2.8 (95% CI: 1.8-4.6) months, respectively. Median OS was 7.5 (95% CI: 5.6-not reached) months. Five neurological adverse events occurred, including 1 grade-4 transient ischemic attack of uncertain imputability and 1 grade-3 neurological deficit; neither required nivolumab discontinuation. Nivolumab intracerebral activity was similar to its reported extracerebral efficacy, with an acceptable safety profile. Prospective and controlled data are needed to determine nivolumab's place in treatment of NSCLC patients with BMs.
Keywords
PD1IQRcytotoxic T-lymphocyte antigen-4GPAcomputed-tomographyNivolumabCTLA4PDL1PFsimmunotherapyprogression-free survivaloverall survivalRECISTNon–small-cell lung cancerNSCLCadverse eventconfidence intervalBrain metastasisCerebral metastasisinterquartile rangeResponse Evaluation Criteria in Solid Tumors
Related Topics
Life Sciences
Biochemistry, Genetics and Molecular Biology
Cancer Research
Authors
Clément Gauvain, Enora Vauléon, Christos Chouaid, Emilie Lerhun, Laurence Jabot, Arnaud Scherpereel, Florent Vinas, Alexis Benjamin Cortot, Isabelle Monnet,